Document:

Second Amendment to the License and Collaboration Agreement

 Exhibit 10.7D 
  
 SECOND AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT 
  
 This SECOND AMENDMENT TO
THE LICENSE AND COLLABORATION AGREEMENT (this “Second Amendment”) is made effective as of the 25th day of November, 2003 by and between Tercica, Inc., a
Delaware corporation having an office located at 651 Gateway Boulevard, Suite 950, South San Francisco, California 94080 (formerly, Tercica Medica, Inc., “TM”) and Genentech, Inc., a Delaware corporation having an office at 1 DNA
Way, South San Francisco, California 94080 (“GNE”). TM and GNE are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
  
 RECITALS 
  
 WHEREAS, GNE and TM have entered into that certain License and Collaboration Agreement, dated April 15, 2002, as amended (the “Agreement”),
whereby GNE transferred certain materials and information to TM relating to IGF-I and granted to TM certain rights to develop and commercialize IGF-I in the United States; and 
  
 WHEREAS, the Parties wish to enter into an amendment to the Agreement in order to amend certain terms set forth therein.

  
 NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
  

	 	1.	All capitalized terms not defined in this Second Amendment shall have the meanings given to them in the Agreement. 

  

	 	2.	The second sentence of Section 8.1(a) shall be amended to read as follows (addition in italics:) “TM agrees that such supply shall not be used for human use,
unless it agrees to the terms of section 8.1 (c) below. 

  

	 	3.	A new section shall be added as Section 8.1 (c) as follows: 

  
 (c) Use of Supply in Humans. In the event TM decides to use any IGF-I received from GNE pursuant to this Section 8.1 in humans as part of a
human clinical trial or otherwise, TM agrees that TM is fully responsible for complying 

 
with any and all applicable laws, regulations and requirements regarding such use, including without limitation, any FDA regulations relating to the QA/QC
testing, safety, expiration extension, labeling and distribution of such product. TM further agrees that it will not include GNE’s name or other GNE information on any label (including any underlabel) on any such product distributed to clinical
sites for human use. It is agreed that any failure to comply with the terms of this subsection (c) shall constitute a “negligent act, omission or willful misconduct” under Section 14.3. For clarity and without limiting the
foregoing, TM shall have the right to use the IGF-I receieved from GNE pursuant to this Section 8.1 in connection with its exercise of its rights under the Agreement and that certain International License and Collaboration Agreement by and
between TM and GNE dated July 25, 2003. 
  

	 	4.	Section 8.2 (a) shall be deleted and replaced with the following (for ease of reference, the second, third and fourth sentences have been changed):

  
 (a) Responsibility. TM shall be
responsible, at its own cost, for the Manufacture of any and all Licensed Product needed for pre-clinical and clinical purposes other than quantities of Licensed Product supplied by GNE pursuant to Section 8.1 above. Effective January 1,
2004, TM agrees to supply any needed IGF-I to the clinical investigators listed in Exhibit E, each of whom had with GNE, a contract in existence prior to the Effective Date for the supply of IGF-I in order to conduct investigator sponsored
trials relating to IGF-I (it is anticipated that the amount of IGF-I needed would remain approximately consistant with previous levels). GNE shall supply the needed IGF-I described in the preceding sentence to such investigators until
December 31, 2003. TM agrees that it will use its best efforts to be able to produce IGF-I suitable for clinical use in humans by June 30, 2004. TM may only hire or otherwise contract with one or more Third Party(ies) to Manufacture any or
all of the Licensed Product needed hereunder with the prior written consent of GNE and GNE consents to TM’s sublicense of its right to Manufacture IGF-I or Licensed Product to Cambrex Corporation (including subsidiaries thereof). GNE further
agrees that TM may hire or contract with such other contract manufacturers as TM may seek to use, provided that GNE has consented to the use of such contract manufacturer, and that GNE will not unreasonably block TM’s ability to find a suitable
contract Manufacturer. 
  

	 	5.	 Except as specifically modified or amended hereby, the Agreement shall remain in full force and effect and, as modified or amended, is hereby ratified, confirmed
and approved. No provision of this Second Amendment may be modified or amended except expressly in a writing signed by both Parties nor shall any terms 

  

 2 

 be waived except expressly in a writing signed by the Party charged therewith. This Second Amendment
shall be governed in accordance with Section 16.11 of the Agreement. 
  
 IN
WITNESS WHEREOF, each of the Parties has executed this Second Amendment in duplicate originals by their proper officers as of the date and year first above written. 
  

							
		
	TERCICA, INC.	  	GENENTECH, INC.
				
	By:	  	 /S/    TIMOTHY P. LYNCH

	  	By:	  	 /S/    JOSEPH MCCRACKEN

	 	  	Name: Tim Lynch	  	 	  	Name: Joseph McCracken
	 	  	Title: Chief Financial Officer	  	 	  	Title: V.P., Business Development

  

 3Separation Agreement and Release

 Exhibit 10.9U 
  
 SEPARATION AGREEMENT AND RELEASE 
  
 RECITALS 
  
 This Separation Agreement and Release (“Agreement”) is made by and between Thomas H. Silberg (“Employee”) and Tercica, Inc.
(“Company”) (jointly referred to as the “Parties”): 
  
 WHEREAS, Employee is employed by the Company; 
  
 WHEREAS, the Company and Employee entered into an At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement (the “Confidentiality Agreement”); 
  
 WHEREAS, by his resignation, Employee’s employment with the Company will
end on June 30, 2005 (the “Resignation Date”); 
  
 WHEREAS, the Company and Employee have entered into Stock Option Agreements granting Employee the option to purchase shares of the Company’s common stock subject to the terms and conditions of the Company’s 2004 Stock Option Plan
and the Stock Option Agreement (the “Stock Option Agreements”); and 
  
 WHEREAS, the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions and demands that the Employee may have against the Company, including, but not limited to, any and
all claims arising or in any way related to Employee’s employment with or separation from the Company. 
  
 NOW THEREFORE, in consideration of the promises made herein, the Parties hereby agree as follows: 
  
 COVENANTS 
  
 1. Consideration. The Company agrees to pay Employee: (a) six
months of base salary, less applicable withholding, in accordance with the Company’s regular payroll practices; and (b) after December 31, 2005, up to a maximum of five months of additional salary, less applicable withholding, in
accordance with the Company’s regular payroll practices, until the earlier of May 31, 2006 or the date Employee commences working full-time for another employer. The Company hereby waives its right to repayment of the $50,000 signing bonus
paid to Employee pursuant to that certain offer letter between the Company and Employee, dated as of April 14, 2004, even though Employee will not have worked for the full 18 months set forth in the offer letter. 
  
 2. Stock. The Parties agree that for purposes of determining the
number of shares of the Company’s common stock that Employee is entitled to purchase from the Company: 87,499 shares shall have vested on June 30, 2005; and on June 30, 2005, the vesting of Employee’s unvested options for the
purchase of 106,252 shares of the Company’s common stock will be accelerated. Employee will have until June 30, 2006 to exercise any of his 87,499 vested and 106,252 accelerated vested option shares. 
  
 3. Benefits. Employee’s dental insurance benefits will cease at
the end of June 2005, subject to Employee’s right to continue his dental insurance under COBRA. Employee’s dental 

 
insurance benefits will be paid by the Company until the earlier of May 31, 2006 or the date Employee is able to obtain coverage for equivalent benefits
from another employer. Employee’s participation in all other benefits and incidents of employment will cease on the Resignation Date. Employee will cease accruing employee benefits, including, but not limited to, vacation time and paid time
off, as of the Resignation Date. 
  
 4. Confidential
Information. Employee shall continue to maintain the confidentiality of all confidential and proprietary information of the Company and shall continue to comply with the terms and conditions of the Confidentiality Agreement between Employee and
the Company. Employee shall return all of the Company’s property and confidential and proprietary information in his possession to the Company. By signing this Agreement, Employee represents and declares under penalty of perjury under the laws
of the State of California that he has returned all Company property. 
  
 5. Payment of Salary. Employee acknowledges and represents that the Company has to date paid all salary, wages, bonuses, accrued vacation, commissions and any and all other benefits due to Employee. On the Resignation Date, Employee
will sign a similar representation. 
  
 6. Release of
Claims. Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Employee by the Company and its officers, managers, supervisors, agents and employees. Employee, on his own behalf, and
on behalf of his respective heirs, family members, executors, agents, and assigns, hereby fully and forever releases the Company and its officers, directors, employees, agents, investors, shareholders, administrators, affiliates, divisions,
subsidiaries, predecessor and successor corporations, and assigns (“the Releasees”), from, and agree not to sue concerning, any claim, duty, obligation or cause of action relating to any matters of any kind, whether presently known or
unknown, suspected or unsuspected, that Employee may possess arising from any omissions, acts or facts that have occurred up until and including the Effective Date of this Agreement including, without limitation: 
  
 (a) any and all claims relating to or arising from Employee’s employment
relationship with the Company and the termination of that relationship; 
  
 (b) any and all claims relating to, or arising from, Employee’s right to purchase, or actual purchase of shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty,
breach of duty under applicable state corporate law, and securities fraud under any state or federal law; 
  
 (c) any and all claims under the law of any jurisdiction including, but not limited to, wrongful discharge of employment; constructive discharge from
employment; termination in violation of public policy; discrimination; breach of contract, both express and implied; breach of a covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional
infliction of emotional distress; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury;
assault; battery; invasion of privacy; false imprisonment; and conversion; 
  
 (d) any and all claims for violation of any federal, state or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination in
Employment Act of 1967, the Americans with Disabilities Act of 1990, the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1974, The Worker 

  

 -2- 

 
Adjustment and Retraining Notification Act, the Older Workers Benefit Protection Act; the Family and Medical Leave Act; the California Family Rights Act; the
California Fair Employment and Housing Act, and the California Labor Code; 
  
 (e) any and all claims for violation of the federal, or any state, constitution; 
  
 (f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; 
  
 (g) any claim for any loss, cost, damage, or expense arising out of any
dispute over the non-withholding or other tax treatment of any of the proceeds received by Employee as a result of this Agreement; and 
  
 (h) any and all claims for attorneys’ fees and costs. 
  
 The Company and Employee agree that the release set forth in this section shall be and remain in effect in all respects as a complete general release as
to the matters released. This release does not extend to any obligations incurred under this Agreement. 
  
 7. Acknowledgement of Waiver of Claims Under ADEA. Employee acknowledges that he is waiving and releasing any rights he may have under the Age
Discrimination in Employment Act of 1967 (“ADEA”) and that this waiver and release is knowing and voluntary. Employee and the Company agree that this waiver and release does not apply to any rights or claims that may arise under ADEA after
the Effective Date of this Agreement. Employee acknowledges that the consideration given for this waiver and release Agreement is in addition to anything of value to which Employee was already entitled. Employee further acknowledges that he has been
advised by this writing that: 
  
 (a) He should consult with an
attorney prior to executing this Agreement; 
  
 (b) He has up to
twenty-one (21) days within which to consider this Agreement; 
  
 (c) He has seven (7) days following his execution of this Agreement to revoke this Agreement; 
  
 (d) this Agreement shall not be effective until the revocation period has expired; and 
  
 (e) nothing in this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of
the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties or costs for doing so, unless specifically authorized by federal law. 
  
 8. Civil Code Section 1542. Employee represents that he is not aware of any claim by him other than the claims
that are released by this Agreement. Employee acknowledges that he has had the opportunity to be advised by legal counsel and is familiar with the provisions of California Civil Code Section 1542, which provides as follows: 
  
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW
OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE 

  

 -3- 

 
RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR. 
  
 Employee, being aware of said code section, agrees to expressly waive any rights he may have thereunder, as well as under
any other statute or common law principles of similar effect. 
  
 9. No Pending or Future Lawsuits. Employee represents that he has no lawsuits, claims, or actions pending in his name, or on behalf of any other person or entity, against the Company or any other person or entity referred to herein.
Employee also represents that he does not intend to bring any claims on his own behalf or on behalf of any other person or entity against the Company or any other person or entity referred to herein. 
  
 10. Application for Employment. [Intentionally Omitted.] 

 
 11. Confidentiality. The Parties acknowledge that Employee’s
agreement to keep the terms and conditions of this Agreement confidential was a material factor on which all parties relied in entering into this Agreement. Employee hereto agrees to use his best efforts to maintain in confidence the existence of
this Agreement, the contents and terms of this Agreement, and the consideration for this Agreement (hereinafter collectively referred to as “Settlement Information”). Employee agrees to take every reasonable precaution to prevent
disclosure of any Settlement Information to third parties, and agrees that there will be no publicity, directly or indirectly, concerning any Settlement Information. Employee agrees to take every precaution to disclose Settlement Information only to
those attorneys, accountants, governmental entities, and family members who have a reasonable need to know of such Settlement Information. 
  
 12. No Cooperation. Employee agrees that he will not encourage, counsel or assist any attorneys or their clients in the presentation or prosecution
of any disputes, differences, grievances, claims, charges, or complaints by any third party against any of the Releasees, unless under a subpoena or other court order to do so. Employee shall inform the Company in writing within three (3) days
of receiving any such subpoena or other court order. 
  
 13.
Mutual Non-Disparagement. Each party agrees to refrain from any defamation, libel or slander of the Releasees, and any tortious interference with the contracts, relationships and prospective economic advantage of the other party on the
Releasees or the Employee agrees that he shall direct all inquiries by potential future employers to Company’s Human Resources department. 
  
 14. Non-Solicitation. Employee agrees that for a period of twelve (12) months immediately following the Effective Date of this Agreement,
Employee shall not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees or consultants to leave their employment, or attempt to do so, either for himself or any other person or entity. 

 
 15. Breach. Employee acknowledges and agrees that any breach of any
provision of this Agreement shall constitute a material breach of this Agreement and shall entitle the Company immediately to recover and/or cease the severance benefits provided to Employee under this Agreement. Employee shall also be responsible
to the Company for all costs, attorneys’ fees and any and all damages incurred by the Company (a) enforcing the obligation, including the bringing of any suit to recover the monetary consideration, and (b) defending against a claim or
suit brought or pursued by Employee in violation of this Agreement. 
  

 -4- 

 16. No Admission of Liability. The Parties understand and acknowledge that this Agreement
constitutes a compromise and settlement of actual or potential disputed claims. No action taken by the Parties hereto, or either of them, either previously or in connection with this Agreement shall be deemed or construed to be: 
  
 (a) an admission of the truth or falsity of any claims made or any potential
claims; or 
  
 (b) an acknowledgment or admission by either party
of any fault or liability whatsoever to the other party or to any third party. 
  
 17. Costs. The Parties shall each bear their own costs, expert fees, attorneys’ fees and other fees incurred in connection with this Agreement, except as provided herein. 
  
 18. Tax Consequences. The Company makes no representations or
warranties with respect to the tax consequences of the payment of any sums to Employee under the terms of this Agreement. Employee agrees and understands that he is responsible for payment, if any, of local, state and/or federal taxes on the sums
paid hereunder by the Company and any penalties or assessments thereon. Employee further agrees to indemnify and hold the Company harmless from any claims, demands, deficiencies, penalties, assessments, executions, judgments, or recoveries by any
government agency against the Company for any amounts claimed due on account of Employee’s failure to pay federal or state taxes or damages sustained by the Company by reason of any such claims, including reasonable attorneys’ fees.

  
 19. Arbitration. The Parties agree that any and all
disputes arising out of the terms of this Agreement, their interpretation, and any of the matters herein released, shall be subject to binding arbitration in San Mateo County before the American Arbitration Association under its National Rules for
the Resolution of Employment Disputes, supplemented by the California Code of Civil Procedure. The Parties agree that the prevailing party in any arbitration shall be entitled to injunctive relief in any court of competent jurisdiction to enforce
the arbitration award. The Parties agree that the prevailing party in any arbitration shall be awarded its reasonable attorneys’ fees and costs. The Parties hereby agree to waive their right to have any dispute between them resolved in a
court of law by a judge or jury. This paragraph will not prevent either party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over the Parties and the subject matter of their dispute relating
to Employee’s obligations under this Agreement and the Confidentiality Agreement. 
  
 20. Authority. The Company represents and warrants that the undersigned has the authority to act on behalf of the Company and to bind the Company and all who may claim through it to the terms and conditions of
this Agreement. Employee represents and warrants that he has the capacity to act on his own behalf and on behalf of all who might claim through him to bind them to the terms and conditions of this Agreement. Each party warrants and represents that
there are no liens or claims of lien or assignments in law or equity or otherwise of or against any of the claims or causes of action released herein. 
  
 21. No Representations. Each party represents that it has had the opportunity to consult with an attorney, and has carefully read and understands
the scope and effect of the provisions of this Agreement. In entering into this Agreement, neither party has relied upon any representations or statements made by the other party hereto which are not specifically set forth in this Agreement.

  

 -5- 

 22. Severability. In the event that any provision, or any portion thereof, becomes or is declared
by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision or portion of said provision. 
  
 23. Entire Agreement. This Agreement represents the entire agreement and understanding between the Company and
Employee concerning the subject matter of this Agreement and Employee’s relationship with the Company, and supersedes and replaces any and all prior agreements and understandings between the Parties concerning the subject matter of this
Agreement and Employee’s relationship with the Company, with the exception of the Stock Option Agreement, the Stock Plan and the Confidentiality Agreement and the Stock Option Agreements. 
  
 24. No Waiver. The failure of the Company to insist upon the
performance of any of the terms and conditions in this Agreement, or the failure to prosecute any breach of any of the terms and conditions of this Agreement, shall not be construed thereafter as a waiver of any such terms or conditions. This entire
Agreement shall remain in full force and effect as if no such forbearance or failure of performance had occurred. 
  
 25. No Oral Modification. This Agreement may only be amended in a writing signed by Employee and the Chief Executive Officer of the Company.

  
 26. Governing Law. This Agreement shall be construed,
interpreted, governed, and enforced in accordance with the laws of the State of California, without regard to choice-of-law provisions. Employee hereby consents to personal and exclusive jurisdiction and venue in the State of California. 

 
 27. Effective Date. This Agreement is effective on the eighth day
after it has been signed by employee (the “Effective Date”). 
  
 28. Counterparts. This Agreement may be executed in counterparts, and each counterpart shall have the same force and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned.

  
 29. Voluntary Execution of Agreement. This Agreement is
executed voluntarily and without any duress or undue influence on the part or behalf of the Parties hereto, with the full intent of releasing all claims. The Parties acknowledge that: 
  
 (a) They have read this Agreement; 
  

(b) They have been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of their own choice or that they have
voluntarily declined to seek such counsel; 
  
 (c) They understand
the terms and consequences of this Agreement and of the releases it contains; and 
  
 (d) They are fully aware of the legal and binding effect of this Agreement. 
  

 -6- 

 IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth below.

  

									
	 	 	 	 	COMPANY
					
	Dated:	 	 May 13, 2005

	 	 	 	By:	 	 /s/    Stephen N.
Rosenfield        

	 	 	 	 	 	 	 	 	 Stephen N. Rosenfield
 Senior Vice President of Legal Affairs

			
	 	 	 	 	 Thomas H. Silberg, an individual

				
	Dated:	 	 May 14, 2005

	 	 	 	 /s/    Thomas H.
Silberg        

	 	 	 	 	 	 	Thomas H. Silberg

  

 -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}]]